Larimar Therapeutics, Inc.
corporate_fare Company Profile
Larimar Therapeutics, Inc. (NASDAQ:LRMR) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 26 items for LRMR at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 14 rated 8 or above. Recent SEC coverage for LRMR spans 10-Q, 8-K, 4, DEF 14A.
Recent high-impact activity:
- Larimar 10-Q: $93.5M Nine-Month Loss, $128.7M Cash Into Late Q2 2027, New Fill/Finish Form 483
- Larimar Posts $31.1M Q3 Loss, Cash to Late Q2 2027 Ahead of BLA Acceptance
- Larimar CEO Ben-Maimon Buys 18,050 Shares for ~$50K, Fourth Insider Buy This Week
- Larimar Completes Rolling BLA for Nomlabofusp; $128.7M Cash Runs to Late Q2 2027
- Larimar Q2 2026: Going Concern Warning Despite BLA Progress — Cash Runway Only Into Q3 2027
Financial Snapshot
Short Interest & Short Volume
8.25 days to coverFINRA reported short interest of 10,538,346 shares in LRMR as of the October 30, 2026 settlement, a 28.1% decrease from the prior period — about 8.3 days to cover at its recent average daily volume. On November 20, 2026, 54.4% of LRMR volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.